News Breaks |
|
|
| March 3, 2013 |
| 16:20 EDT |  | CELG, AMGN, ABBV | Celgene psoriasis drug results fall short of prior trials data, WSJ says
Celgene's (CELG) Apremilast, an experimental anti-inflammatory treatment for psoriasis, significantly helped a smaller proportion of patients than in an earlier study, says the Wall Street Journal, adding that these results "could damp hopes for the drug's market potential" to compete with other generic topical creams and branded drugs from AbbVie (ABBV) and Amgen (AMGN), says the Wall Street Journal. Reference Link |
|
|
News For CELG;ABBV;AMGN From The Last 14 Days Check below for free stories on CELG;ABBV;AMGN the last two weeks. |
|
|
| May 20, 2013 |
| 10:51 EDT |  | ABBV | AbbVie initiates Phase 3 clinical study for atrasentan
 Subscribe for More Information |
|
| 09:51 EDT |  | CELG | Celgene management to meet with JPMorgan
Meetings to be held in Boston on May 22-23 hosted by JPMorgan. |
|
| 07:42 EDT | | ABBV | Cohasset Associates to host a conference
National Conference on Managing Electronic Records is being held in Chicago on May 20-22. |
|
| May 17, 2013 |
| 05:51 EDT |  | CELG | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information |
|
| 05:15 EDT | | ABBV | Galapagos, AbbVie extend GLPG0634 collaboration
Galapagos and AbbVie announced an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 of 2015, AbbVie will pay Galapagos $50M. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities. Galapagos will start an 20-week, Phase 2A/B study with GLPG0634 in 180 patients suffering from Crohn's disease by early 2014. |
|
| May 16, 2013 |
| 11:50 EDT | | CELG | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 08:55 EDT | | ABBV | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 17:26 EDT | | ABBV | Third Point gives quarterly update on stakes
NEW STAKES: Virgin Media (VMED), Tiffany (TIF), B/E Aerospace (BEAV), Anadarko (APC), and Thermo Fisher (TMO). INCREASED STAKES: International Paper (IP), Abbvie (ABBV), TransDigm (TDG), Constellation Brands (STZ), and Dollar General (DG). DECREASED STAKES: Delphi (DLPH), Murphy Oil (MUR), AIG (AIG), LyondellBasell (LYB), and Liberty Global (LBTYA). LIQUIDATED STAKES: Tesoro (TSO), Morgan Stanley (MS), Symantec (SYMC), Herbalife (HLF), and Illumina (ILMN). |
|
| 10:13 EDT |  | ABBV | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:59 EDT | | ABBV | AbbVie initiated with an Outperform at Cowen
Subscribe for More Information |
| |
| May 14, 2013 |
| 10:20 EDT | | ABBV | AbbVie volatility at 22 into ASCO
Subscribe for More Information |
|
| 09:27 EDT | | ABBV | AbbVie and Alvine Pharmaceutical enter into collaboration
Subscribe for More Information |
|
| 07:24 EDT | | ABBV | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 08:55 EDT | | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| May 10, 2013 |
| 16:34 EDT | | ABBV | AbbVie chief scientific officer Leonard to retire
AbbVie disclosed in a regulatory filing that John Leonard, senior VP, chief scientific officer, has informed the company that he will be retiring from the company in the next few months and will be involved in the transition process for naming his successor. |
|
| May 9, 2013 |
| 16:48 EDT | | AMGN | Amgen, Zhejiang Beta Pharma announce joint venture in China
Subscribe for More Information |
|
| May 7, 2013 |
| 16:31 EDT | | AMGN | Amgen announces Phase 3 head-to-head study of Vectibix versus Erbitux
Subscribe for More Information |
|
| 07:18 EDT |  | CELG | Barclays has increased confidence in Celgene's re-filing of Revlimid
Subscribe for More Information |
|
|
|
|
|
